AstraZeneca (LON:AZN) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

AstraZeneca PLC (LON:AZN)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as £119.08 ($149.88). AstraZeneca shares last traded at £117.08 ($147.36), with a volume of 2,988,152 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AZN. JPMorgan Chase & Co. reissued an “overweight” rating and set a £140 ($176.21) price target on shares of AstraZeneca in a research report on Friday, November 22nd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 140 ($1.76) price target on shares of AstraZeneca in a research report on Monday, January 27th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($94.94).

AstraZeneca Price Performance

The company has a 50 day moving average of £108.87 and a 200-day moving average of £114.78. The stock has a market capitalization of £225.27 billion, a P/E ratio of 32.09, a PEG ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83.

Insider Buying and Selling at AstraZeneca

In related news, insider Tony Mok bought 1,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average cost of £126.80 ($159.60) per share, for a total transaction of £190,200 ($239,395.85). 0.04% of the stock is currently owned by company insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.